Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib or Trametinib and Clofarabine for High-risk/Refractory LCH
NCT07022834Phase 2Recruiting
- Sponsor
- West China Second University Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib, trametinib and clofarabine in Langerhans cell histiocytosis (LCH), sponsored by West China Second University Hospital. Primary endpoint: Progression Free Survival at 24 months. Started Jun 2025; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinibclofarabine
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT07022834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07022834.